slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 42,811-42,840
Pages 10,126
Rows per page 30
Component
42,811-42,840 of 303,780
31
Includes a legend for independent directors and committee chairs.Nano Dimension | Shareholder Engagement Presentation Deck | 34 slides · Nano Dimension
Shareholder letter Investor relations Beat · Action2 hits
32
The chart uses a visual representation of directors as blocks, with light blue for general directors and dark blue for independent directors.Nano Dimension | Shareholder Engagement Presentation Deck | 34 slides · Nano Dimension
Shareholder letter Investor relations Beat · Action2 hits
33
The slide uses a Venn diagram to represent engagement and a list with arrows to represent rights protections.Nano Dimension | Shareholder Engagement Presentation Deck | 34 slides · Nano Dimension
Shareholder letter Investor relations Beat · Action2 hits
34
Uses a numbered list format to present key arguments for the board's re-election.Nano Dimension | Shareholder Engagement Presentation Deck | 34 slides · Nano Dimension
Shareholder letter Investor relations Beat · Action2 hits
16
The slide uses a combination of a product screenshot and four key metrics to validate the 'social commerce' thesis.Nextdoor | Investor Presentation Deck | 34 slides · Nextdoor
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction2 hits
06
The slide uses a logo grid to establish credibility and market presence.NextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations Beat · SolutionLoop · Why Now2 hits
08
The slide details a capital raise structure involving senior secured notes and warrants.NextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet2 hits
03
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Attention2 hits
07
The slide highlights a specific operational deployment plan for 9 mobile fuelers.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter2 hits
09
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Loop · Pattern Hunter2 hits
12
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter2 hits
04
The slide combines a retrospective traction report with a mission/vision statement.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 2 hits
05
Includes a grid of headshots for the leadership team and lists for board members and advisors, plus a logo-grid for prior FDA approvals.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 2 hits
09
Nuvalent | Investor Presentation Deck | 39 slidesNuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
10
The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction2 hits
11
The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction2 hits
26
Slide 26 of a clinical presentation.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 2 hits
27
The slide uses a list of icons to represent key features of the drug candidate.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 2 hits
28
The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 2 hits
29
The table uses a green/white color coding to highlight positive attributes of NVL-655 compared to competitors.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 2 hits
33
The slide outlines the key therapeutic advantages of the drug candidate NVL-330.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 2 hits
36
The slide uses a cascading hexagonal process flow to illustrate the methodology.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 2 hits
01
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 2 hits
02
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 2 hits
04
The slide uses a visual association between the three executives and the logos of companies/products they have been associated with.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Team2 hits
08
Includes a molecular pathway diagram and a Western blot image as evidence.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
09
The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
10
Includes a patient-derived xenograft (PDX) study workflow diagram and a tumor volume growth curve.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
11
The chart shows tumor volume reduction over 28 days compared to vehicle control.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
16
Uses a structural biology diagram to illustrate mechanism of action.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits